Medicaid Drug Spending
Medicaid, the health program for low-income Americans, is run by each state, and every state reports what it paid pharmacies for each drug. This adds those reports up by drug and by state, before the rebates drug makers pay back.
What state Medicaid programs paid pharmacies for 1,915 outpatient drugs in 2025, before manufacturer rebates, with prescriptions, the change from 2024 and each state's share, from CMS's State Drug Utilization Data.
- Paid in 2025: $116.9B
- Change from 2024: +8%
- Prescriptions: 725M
- Top drug: Ozempic, $3.8B
- Since 2016: 78% more
Paid per Year
All outpatient drugs, before rebates.
Biggest Drugs, 2025
By amount paid, before rebates.
- Ozempic$3.8B
- Biktarvy$3.6B
- Humira$3.5B
- Dupixent$3.0B
- Wegovy$2.6B
- Jardiance$2.5B
- Invega$2.4B
- Trulicity$1.9B
- Zepbound$1.8B
- Skyrizi$1.8B
Biggest States, 2025
Fee-for-service and managed care together.
- California$18.3B
- New York$12.7B
- Pennsylvania$5.4B
- Ohio$4.8B
- North Carolina$4.7B
- Michigan$4.2B
- Texas$3.7B
- Illinois$3.3B
- Florida$3.3B
- Indiana$2.9B
Every Drug, 2025
Largest first; sort by change or cost per prescription, or search a drug.| Top state | |||||
|---|---|---|---|---|---|
| Ozempic | $3.75B | 3,695,710 | $1,016 | +11% | California |
| Biktarvy | $3.56B | 780,134 | $4,558 | +9% | New York |
| Humira | $3.49B | 386,973 | $9,020 | -17% | California |
| Dupixent | $3.04B | 765,585 | $3,974 | +29% | New York |
| Wegovy | $2.60B | 1,995,718 | $1,303 | +82% | California |
| Jardiance | $2.52B | 2,945,841 | $855 | +13% | California |
| Invega | $2.40B | 704,944 | $3,407 | +5% | California |
| Trulicity | $1.95B | 1,940,795 | $1,004 | -10% | Ohio |
| Zepbound | $1.81B | 1,723,702 | $1,049 | +534% | California |
| Skyrizi | $1.76B | 86,735 | $20,276 | +58% | California |
| Vraylar | $1.63B | 1,096,927 | $1,483 | +14% | Ohio |
| Mounjaro | $1.52B | 1,416,807 | $1,070 | +65% | California |
| Trikafta | $1.45B | 53,971 | $26,862 | -7% | California |
| Cosentyx | $1.43B | 154,503 | $9,252 | +19% | California |
| Eliquis | $1.42B | 2,188,265 | $650 | +10% | California |
| Stelara | $1.37B | 53,532 | $25,525 | -16% | California |
| Enbrel | $1.11B | 140,549 | $7,932 | +3% | California |
| Vyvanse | $1.08B | 2,886,437 | $375 | -4% | Wisconsin |
| Abilify | $1.03B | 367,670 | $2,800 | +13% | California |
| Hemlibra | $995.0M | 29,976 | $33,193 | +7% | California |
| Keytruda | $892.5M | 78,912 | $11,310 | +4% | California |
| Farxiga | $890.9M | 1,129,790 | $789 | +9% | California |
| Rinvoq | $833.7M | 111,488 | $7,478 | +44% | California |
| Suboxone | $814.8M | 2,354,516 | $346 | -9% | Maryland |
| Symbicort | $702.0M | 2,850,515 | $246 | +10% | New York |
| Sublocade | $687.3M | 343,837 | $1,999 | +26% | Pennsylvania |
| Ingrezza | $675.3M | 86,668 | $7,792 | +15% | California |
| Nurtec | $632.7M | 499,751 | $1,266 | +18% | New York |
| Taltz | $616.4M | 76,699 | $8,037 | +1% | Pennsylvania |
| Mavyret | $599.1M | 45,561 | $13,150 | -3% | California |
| Linzess | $586.6M | 924,006 | $635 | +22% | California |
| Epidiolex | $570.9M | 152,460 | $3,745 | +10% | California |
| Trelegy | $554.1M | 779,112 | $711 | +15% | New York |
| Norditropi | $547.8M | 93,747 | $5,843 | +42% | New York |
| Fluticason | $546.2M | 11,537,335 | $47 | -13% | California |
| Entresto | $546.1M | 666,978 | $819 | -13% | New York |
| Tremfya | $533.0M | 36,317 | $14,677 | +51% | New York |
| Rexulti | $525.8M | 351,599 | $1,495 | +12% | Michigan |
| Austedo | $512.7M | 66,688 | $7,688 | +31% | California |
| Xarelto | $469.6M | 666,827 | $704 | -4% | California |
| Descovy | $466.3M | 183,537 | $2,541 | -1% | California |
| Ocrevus | $451.4M | 14,870 | $30,355 | +6% | New York |
| Kesimpta | $447.6M | 44,144 | $10,139 | +34% | California |
| Xolair | $440.9M | 160,698 | $2,744 | +17% | New York |
| Verzenio | $439.9M | 28,782 | $15,285 | +10% | California |
| Caplyta | $426.8M | 256,826 | $1,662 | +35% | California |
| Bimzelx | $425.8M | 22,379 | $19,025 | +825% | New York |
| Creon | $422.0M | 211,510 | $1,995 | +5% | New York |
| Insulin | $400.7M | 2,598,418 | $154 | +19% | New York |
| Evrysdi | $399.0M | 15,567 | $25,628 | +15% | California |
States report every outpatient drug their Medicaid programs pay for under the Medicaid Drug Rebate Program, fee-for-service and managed care. Amounts are what pharmacies were paid, before the rebates manufacturers pay back to Medicaid, which are confidential per drug. CMS cuts product names to 10 characters, so a drug here is the first word of its name and strengths are added together. Counts under 11 are suppressed by CMS and left out. The current year appears once all four quarters are in. Refreshed weekly. CMS, State Drug Utilization Data